Phase I Trial of Afatinib in Combination With 3 Weekly Trastuzumab in Patients With Tumours Overexpressing HER2. Once the MTD of Afatinib With 3 Weekly Trastuzumab Was Established the Safety of This Dose Will be Assessed Also in Combination With Weekly Trastuzumab
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2016
At a glance
- Drugs Afatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 28 Jun 2016 Status changed from active, no longer recruiting to completed.
- 11 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016.